Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

The wobbly status of ketolides: where do we stand?

Georgopapadakou NH.

Expert Opin Investig Drugs. 2014 Oct;23(10):1313-9. doi: 10.1517/13543784.2014.954036. Epub 2014 Aug 25.

PMID:
25154307
2.

Prospects for new antibacterials: can we do better?

Georgopapadakou NH.

Expert Opin Investig Drugs. 2014 Feb;23(2):145-8. doi: 10.1517/13543784.2014.847087. Epub 2013 Nov 11.

PMID:
24205783
3.

Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ.

J Clin Microbiol. 2009 Dec;47(12):3797-804. doi: 10.1128/JCM.00618-09. Epub 2009 Sep 30.

4.

N,N-Dichloroaminosulfonic acids as novel topical antimicrobial agents.

Low E, Nair S, Shiau T, Belisle B, Debabov D, Celeri C, Zuck M, Najafi R, Georgopapadakou N, Jain R.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):196-8. doi: 10.1016/j.bmcl.2008.10.114. Epub 2008 Oct 31.

PMID:
19010674
5.

Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2007 Aug-Oct;10(4-5):182-93. Epub 2007 Sep 12.

PMID:
17855157
6.

Discontinued drugs in 2005: anti-infectives.

Georgopapadakou N.

Expert Opin Investig Drugs. 2007 Jan;16(1):1-10. Review.

PMID:
17155849
7.

Fungal diagnostics, pathogenesis and chemotherapy symposia.

Georgopapadakou NH.

IDrugs. 1998 Dec;1(8):841-2.

PMID:
16196467
8.

Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2005 Aug;8(4):183-97. Epub 2005 Sep 9.

PMID:
16154800
9.

Seminal contributions to the role of transport in antibacterial drug resistance recognized in a recent award.

Georgopapadakou N.

Drug Resist Updat. 2005 Feb-Apr;8(1-2):3-4. No abstract available.

PMID:
15939337
10.

Beta-lactamase inhibitors: evolving compounds for evolving resistance targets.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2004 Oct;13(10):1307-18. Review.

PMID:
15461559
11.

New cancer therapeutics: target-specific in, cytotoxics out?

Broxterman HJ, Georgopapadakou NH.

Drug Resist Updat. 2004 Apr;7(2):79-87.

PMID:
15158764
12.

Superbugs and Superdrugs: a focus on antibacterials--6th annual SMi conference.

Georgopapadakou N.

Expert Opin Emerg Drugs. 2004 May;9(1):191-5. No abstract available.

PMID:
15155144
13.

Mechanism of action of NB2001 and NB2030, novel antibacterial agents activated by beta-lactamases.

Stone GW, Zhang Q, Castillo R, Doppalapudi VR, Bueno AR, Lee JY, Li Q, Sergeeva M, Khambatta G, Georgopapadakou NH.

Antimicrob Agents Chemother. 2004 Feb;48(2):477-83.

14.

Infectious disease 2001: drug resistance, new drugs.

Georgopapadakou NH.

Drug Resist Updat. 2002 Oct;5(5):181-91.

PMID:
12450783
15.

A diversity of therapeutic targets.

Georgopapadakou NH.

Expert Opin Ther Targets. 2002 Jun;6(3):255-6. No abstract available.

PMID:
12223067
16.

Antifungals targeted to protein modification: focus on protein N-myristoyltransferase.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2002 Aug;11(8):1117-25. Review.

PMID:
12150705
17.

A continuous fluorometric assay of myristoyl-coenzyme A:protein N-myristoyltransferase.

Pennise CR, Georgopapadakou NH, Collins RD, Graciani NR, Pompliano DL.

Anal Biochem. 2002 Jan 15;300(2):275-7. No abstract available.

PMID:
11779123
18.

Cancer research 2001: drug resistance, new targets and drug combinations.

Broxterman HJ, Georgopapadakou N.

Drug Resist Updat. 2001 Jun;4(3):197-209.

PMID:
11768333
19.

39(th)Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, USA, 26-29 September 1999.

Georgopapadakou NH.

Drug Resist Updat. 1999 Oct;2(5):335-340. No abstract available.

PMID:
11504508
20.

EDITORIAL.

Georgopapadakou NH, Broxterman H, Chambers H, Cowman AF, Wainberg M.

Drug Resist Updat. 1999 Feb;2(1):1. No abstract available.

PMID:
11504462
21.

Infectious disease 2000: drug resistance and new drugs.

Georgopapadakou NH.

Drug Resist Updat. 2000 Oct;3(5):265-269.

PMID:
11498394
22.

Cancer research 2000: drug resistance, new targets and drugs in development.

Broxterman HJ, Georgopapadakou N.

Drug Resist Updat. 2000 Jun;3(3):133-138.

PMID:
11498376
23.

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2001 Feb;10(2):269-80. Review.

PMID:
11178340
24.

Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase.

Georgopapadakou NH.

Expert Opin Investig Drugs. 2000 Aug;9(8):1787-96. Review.

PMID:
11060777
25.

Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species.

Zhong W, Jeffries MW, Georgopapadakou NH.

Antimicrob Agents Chemother. 2000 Mar;44(3):651-3.

26.

Inhibition of yeast inositol phosphorylceramide synthase by aureobasidin A measured by a fluorometric assay.

Zhong W, Murphy DJ, Georgopapadakou NH.

FEBS Lett. 1999 Dec 17;463(3):241-4.

27.

Antifungals: mechanism of action and resistance, established and novel drugs.

Georgopapadakou NH.

Curr Opin Microbiol. 1998 Oct;1(5):547-57. Review.

PMID:
10066533
28.

Antifungals targeted to the cell wall.

Georgopapadakou NH.

Expert Opin Investig Drugs. 1997 Feb;6(2):147-50.

PMID:
15989597
29.

Mammalian microsomal and soluble Ras-processing peptidase activities are distinct.

Hitz AM, Georgopapadakou NH.

FEBS Lett. 1996 Aug 12;391(3):310-2.

30.

Does cephalothin inhibit matrix metalloproteinases?

Georgopapadakou NH.

Antimicrob Agents Chemother. 1996 Aug;40(8):1969-70. No abstract available.

31.

Antifungal agents: chemotherapeutic targets and immunologic strategies.

Georgopapadakou NH, Walsh TJ.

Antimicrob Agents Chemother. 1996 Feb;40(2):279-91. Review. No abstract available.

32.

Inhibitors of farnesyltransferase and Ras processing peptidase.

Hall CC, Watkins JD, Ferguson SB, Foley LH, Georgopapadakou NH.

Biochem Biophys Res Commun. 1995 Dec 26;217(3):728-32.

PMID:
8554591
33.

The fungal cell wall as a drug target.

Georgopapadakou NH, Tkacz JS.

Trends Microbiol. 1995 Mar;3(3):98-104. Review.

PMID:
7773595
34.

Low-level resistance to the cephalosporin 3'-quinolone ester Ro 23-9424 in Escherichia coli.

Chapman JS, Bertasso A, Cummings LM, Georgopapadakou NH.

Antimicrob Agents Chemother. 1995 Feb;39(2):564-6.

35.

A radiometric assay for Ras-processing peptidase using an enzymatically radiolabeled peptide.

Georgopapadakou NH, Hall CC, Lambros T, Liu W, Watkins JD.

Anal Biochem. 1994 May 1;218(2):273-7.

PMID:
8074280
36.

beta-Lactamase hydrolysis of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines.

Georgopapadakou NH, McCaffrey C.

Antimicrob Agents Chemother. 1994 May;38(5):959-62.

37.

Human mycoses: drugs and targets for emerging pathogens.

Georgopapadakou NH, Walsh TJ.

Science. 1994 Apr 15;264(5157):371-3. Review. No abstract available.

PMID:
8153622
38.

Dual-action cephalosporins incorporating a 3'-tertiary-amine-linked quinolone.

Albrecht HA, Beskid G, Christenson JG, Deitcher KH, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Wei CC.

J Med Chem. 1994 Feb 4;37(3):400-7.

PMID:
8308866
39.

Penicillin-binding proteins and bacterial resistance to beta-lactams.

Georgopapadakou NH.

Antimicrob Agents Chemother. 1993 Oct;37(10):2045-53. Review. No abstract available.

40.

Porins and lipopolysaccharide of Escherichia coli ATCC 25922 and isogenic rough mutants.

Rivera M, Bertasso A, McCaffrey C, Georgopapadakou NH.

FEMS Microbiol Lett. 1993 Apr 1;108(2):183-7.

PMID:
8387443
41.

Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1993 Mar;37(3):559-65.

42.

Screening assays for protein synthesis inhibitors.

Hall CC, Bertasso A, Watkins JD, Georgopapadakou NH.

J Antibiot (Tokyo). 1992 Oct;45(10):1697-9. No abstract available.

43.

Effects of squalene epoxidase inhibitors on Candida albicans.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.

44.

Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

McCaffrey C, Bertasso A, Pace J, Georgopapadakou NH.

Antimicrob Agents Chemother. 1992 Aug;36(8):1601-5.

45.

Dual-action penems and carbapenems.

Corraz AJ, Dax SL, Dunlap NK, Georgopapadakou NH, Keith DD, Pruess DL, Rossman PL, Then R, Unowsky J, Wei CC.

J Med Chem. 1992 May 15;35(10):1828-39.

PMID:
1588561
46.

Effects of quinolones on nucleoid segregation in Escherichia coli.

Georgopapadakou NH, Bertasso A.

Antimicrob Agents Chemother. 1991 Dec;35(12):2645-8.

47.
48.

Dual-action cephalosporins: cephalosporin 3'-quinolone carbamates.

Albrecht HA, Beskid G, Christenson JG, Georgopapadakou NH, Keith DD, Konzelmann FM, Pruess DL, Rossman PL, Wei CC.

J Med Chem. 1991 Sep;34(9):2857-64.

PMID:
1910090
49.
50.

Dual-action cephalosporins: cephalosporin 3'-quaternary ammonium quinolones.

Albrecht HA, Beskid G, Christenson JG, Durkin JW, Fallat V, Georgopapadakou NH, Keith DD, Konzelmann FM, Lipschitz ER, McGarry DH, et al.

J Med Chem. 1991 Feb;34(2):669-75.

PMID:
1847430

Supplemental Content

Loading ...
Support Center